Display Settings:

Format

Send to:

Choose Destination
    Adv Appl Microbiol. 2009;66:1-27.

    Multiple effector mechanisms induced by recombinant Listeria monocytogenes anticancer immunotherapeutics.

    Source

    Department of Antibody Technology ImClone Systems, a wholly-owned subsidiary of Eli Lilly & Co. New York, NY 10014, USA.

    Abstract

    Listeria monocytogenes is a facultative intracellular gram-positive bacterium that naturally infects professional antigen presenting cells (APC) to target antigens to both class I and class II antigen processing pathways. This infection process results in the stimulation of strong innate and adaptive immune responses, which make it an ideal candidate for a vaccine vector to deliver heterologous antigens. This ability of L. monocytogenes has been exploited by several researchers over the past decade to specifically deliver tumor-associated antigens that are poorly immunogenic such as self-antigens. This review describes the preclinical studies that have elucidated the multiple immune responses elicited by this bacterium that direct its ability to influence tumor growth.

    PMID:
    19203646
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Click here to read

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk